HC Wainwright & Co. Reiterates Buy on Beam Therapeutics, Maintains $80 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 90.2%

Neg 0% Neu 90.2% Pos 0%

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Beam Therapeutics (NASDAQ:BEAM) with a Buy and maintains $80 price target.